RCPT up +0.70% percent right now. $RCPT High is at 112.17

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
RCPT up +0.70% percent right now. $RCPT High is at 112.17 and the Low 108.25 with current volume of 263,421.

Recent News posted below.

RCPT Receptos Inc Recent Headline News

Receptos to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Thu Nov 06, 3:03PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Credit Suisse Healthcare Conference at The Biltmore Hotel in Phoenix, Arizona. The presentation is scheduled for Wednesday, November 12 at 8:30am. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.80 (+0.56)

Receptos' (RCPT) CEO Faheem Hasnain on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 11:46AM CST

RCPT: 109.80 (+0.56)

Receptos posts 3Q loss
Automated Insights - Tue Nov 04, 7:19AM CST
SAN DIEGO (AP) _ Receptos Inc. (RCPT) on Tuesday reported a loss of $32.2 million in its third quarter.
RCPT: 109.80 (+0.56)

Receptos misses by $0.23, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 6:04AM CST

RCPT: 109.80 (+0.56)

Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 6:00AM CST
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
RCPT: 109.80 (+0.56)

Receptos to Present at Nomura BioPharma Conference
GlobeNewswire - Mon Nov 03, 3:01PM CST
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that Faheem Hasnain, its President and Chief Executive Officer, will be presenting at the Nomura BioPharma Conference at the Mandarin Oriental Hotel in Boston. The presentation is scheduled for Thursday, November 6 at 2:15pm Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 14 days after the event.
RCPT: 109.80 (+0.56)

Clinical Trial Results, Product Approval Letter, Financial Results, and Upcoming Event - Research Reports on Receptos, Wright, United Therapeutics, Abbott and CareFusion
PR Newswire - Fri Oct 31, 7:40AM CDT
Today, Analysts Review released its research reports regarding Receptos Inc. (NASDAQ: RCPT), Wright Medical Group Inc. (NASDAQ: WMGI), United Therapeutics Corporation (NASDAQ: UTHR), Abbott Laboratories (NYSE: ABT) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7594-100free.
ABT: 44.06 (+0.69), WMGI: 27.93 (-0.02), CFN: 57.42 (+0.14), UTHR: 125.12 (+0.91), RCPT: 109.80 (+0.56), WMGIZ: 4.40 (+0.09)

Receptos to Hold Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 29, 3:12PM CDT
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce financial results for the third quarter ended September 30, 2014 on Tuesday, November 4 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time (5:00 a.m. Pacific time).
RCPT: 109.80 (+0.56)

Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 52.01 (+1.84), PTLA: 27.47 (+0.08), RCPT: 109.80 (+0.56), IG: 9.59 (+0.14)

Nasdaq stocks posting largest percentage increases
AP - Tue Oct 28, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
VDSI: 28.24 (+1.61), ECHO: 27.93 (+0.60), LAYN: 7.60 (+0.08), NVAX: 5.17 (+0.22), SCYX: 9.50 (+0.50), RCPT: 109.80 (+0.56), TRNX: 26.06 (+0.56), IDTI: 18.11 (+0.38), SANM: 25.33 (-0.27)

Twitter and Amgen are big market movers
AP - Tue Oct 28, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.33 (-0.06), KSS: 56.60 (-0.62), MU: 33.00 (-0.01), PFE: 30.25 (+0.33), HAL: 53.57 (-0.29), AMGN: 163.03 (+2.78), NQ: 7.55 (+0.37), RGC: 22.50 (+0.35), MS: 35.75 (+0.09), MSG: 74.82 (-0.33), NVAX: 5.17 (+0.22), CQB: 14.44 (+0.01), SRPT: 16.02 (-0.10), RCPT: 109.80 (+0.56), TWTR: 39.67 (-0.64), PTIE: 1.68 (-0.03)

Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 163.03 (+2.78), RCPT: 109.80 (+0.56), NVS: 92.61 (+0.85)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:46AM CDT

RGSE: 0.85 (-0.08), AMKR: 6.33 (-0.06), VTAE: 17.23 (+2.79), ASTI: 1.89 (-0.09), CLF: 11.23 (+0.06), LMNX: 18.22 (+0.18), IDTI: 18.11 (+0.38), HNR: 3.02 (-0.15), VDSI: 28.24 (+1.61), DCO: 23.68 (-0.36), MDCO: 24.40 (-0.19), SCYX: 9.50 (+0.50), VGGL: 1.60 (+0.02), RCPT: 109.80 (+0.56), IBIO: 1.23 (+0.07), SNY: 46.35 (+0.66), TWTR: 39.67 (-0.64), DPW: 1.63 (-0.04), MERU: 4.03 (+0.02), SANM: 25.33 (-0.27)

Receptos Soars After Lead Drug Racks Up Another Win
at Investor's Business Daily - Tue Oct 28, 10:46AM CDT
Receptos (RCPT) stock jumped more than 47% to a new high above 99 in morning trading on the stock market today, and the company got multiple price-target increases after its bowel-disease drug succeeded in a midstage trial. Receptos announced late...
JNJ: 108.89 (+0.69), RCPT: 109.80 (+0.56), ABBV: 63.76 (+2.26)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 8:13AM CDT

KSS: 56.60 (-0.62), FRO: 1.38 (-0.02), ASTI: 1.89 (-0.09), TRNX: 26.06 (+0.56), CVLT: 48.21 (+0.15), UBS: 17.13 (+0.07), BWLD: 158.94 (+1.43), HASI: 13.68 (+0.05), COH: 33.81 (+0.15), VDSI: 28.24 (+1.61), MSG: 74.82 (-0.33), NVO: 43.31 (-0.38), ACI: 2.51 (-0.35), RCPT: 109.80 (+0.56), TWTR: 39.67 (-0.64), SNY: 46.35 (+0.66), FOLD: 6.20 (+0.48), NE: 21.03 (-0.80)

Stock Futures Positive, Steady; Vasco Rockets, Twitter Fades
at Investor's Business Daily - Tue Oct 28, 8:01AM CDT
Stock futures rolled up moderate gains ahead of Tuesday's open, as investors geared up for a session with many moving parts. Dow futures were steady, trading 73.1 points above fair market value. Nasdaq 100 futures were up a strong 19.4 points, and...
WHR: 174.04 (-1.77), VDSI: 28.24 (+1.61), RCPT: 109.80 (+0.56), BP: 41.90 (-0.16), TWTR: 39.67 (-0.64), AET: 83.86 (+1.57)

Receptos up premarket on UC trial results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 7:09AM CDT

RCPT: 109.80 (+0.56)

RECEPTOS
at Investor's Business Daily - Mon Oct 27, 5:48PM CDT
RECEPTOS (RCPT), a biotech, reported positive phase 2 trial results for its RPC1063 treatment for ulcerative colitis. Shares shot up 25.1% to 85.02.
RCPT: 109.80 (+0.56)

Receptos lead product successful in Phase 2 for UC at higher dose
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 5:25PM CDT

RCPT: 109.80 (+0.56)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 220

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 90

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 408

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 39

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 208

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Precious Metals and Energy Investors' Strategies

Updated Category News Views 143

Current Trends in Precious Metals The appeal of precious metals like gold and silver continues to gather momentum, particularly in light of recent global events. Many analysts believe that geopolitical tensions have created a catalyst for increased interest in gold as a safe haven. As governments grapple with economic challenges, investors are keenly observing changes in...

Continue Reading
Understanding P/E Ratios in the Context of Casey's General Stores

Updated Category News Views 175

Analyzing P/E Ratios for Investment Decisions In today’s market, understanding the performance metrics of stocks is vital. Currently, Casey's General Stores Inc. (NASDAQ: CASY) is noted at an impressive share price of $536.66. This reflects a modest increase of 0.33%. In examining market trends, the past month saw a slight decline of 4.39% in share value. However,...

Continue Reading
China's New Lending Outlook: Economic Recovery Strategies

Updated Category News Views 135

China's Recent New Lending Trends Recent updates reveal a significant rise in new bank lending in China. However, it didn't quite meet expectations, as analysts had hoped for a stronger performance. After disappointing figures in July, which hit a 15-year low, new data shows that Chinese banks issued around 900 billion yuan (approximately $126.86 billion) in new loans in...

Continue Reading
ParkOhio Shares Important Quarterly Dividend News for Investors

Updated Category News Views 177

ParkOhio Holdings Announces Latest Dividend Declaration Park-Ohio Holdings Corp. (NASDAQ: PKOH) recently declared a significant quarterly cash dividend of $0.125 per share to its common stockholders. This distribution demonstrates the company's ongoing commitment to providing returns to its shareholders. This dividend will be payable soon, marking another positive...

Continue Reading
Investigation Launched for Tourmaline Bio's Shareholders

Updated Category News Views 259

Investigation Overview on Tourmaline Bio, Inc. Recently, Monteverde & Associates PC, a renowned law firm, has initiated an investigation concerning Tourmaline Bio, Inc. (NASDAQ: TRML) and its proposed sale to Novartis AG. This potential acquisition raises several questions about the fairness of the deal, specifically regarding the cash payment offered to shareholders....

Continue Reading